Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.65 |
| ▸ | GSK3A | P49840 | 1/20 | 0.65 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.65 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.65 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | EEF2K | O00418 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PRKX | P51817 | 1/20 | 0.48 |
| ▸ | NEK4 | P51957 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032516 | 0.89 | TAOK1 (0.50) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL31414297 | 0.84 | ROCK2 (0.49) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL20139305 | 0.84 | ROCK2 (0.49) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL13539429 | 0.84 | SLC22A12 (0.52) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL13165280 | 0.83 | ROCK2 (0.46) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL2481963 | 0.83 | EGFR (0.48) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL10588 | 0.83 | ROCK2 (0.46) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL10325766 | 0.82 | ROCK2 (0.46) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL12692642 | 0.82 | TAOK1 (0.46) | TAOK1CLK4CHEK1AURKADAPK3 | |
| SCHEMBL30147488 | 0.82 | ROCK2 (0.46) | TAOK1CLK4CHEK1AURKADAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| EP-4615836-A1 | INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE METHODS OF USE THEREOF | Flagship Pioneering Innovations VI, LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| US-20240287003-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | UNIVERSITE EUROMEDITERRANEENNE DE FES (MA) | 2024-08-29 | — | — | US | disclosed |
| WO-2024102924-A1 | INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE METHODS OF USE THEREOF | FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4337642-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | Universite Euro-Mediterraneenne de Fes (MA) | 2024-03-20 | — | — | EP | disclosed |
| CN-117730074-A | Diuretic acid derivatives as inhibitors of MPRO protease and SARS-COV-2 replication | 菲斯欧洲地中海大学 | 2024-03-19 | — | — | CN | disclosed |
| EP-4334298-A1 | UREA DERIVATIVES WHICH CAN BE USED TO TREAT CANCER | Scorpion Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117343049-A | Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor | 北京泰德制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2004078747-A1 | NOVEL CYANOPYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078748-A2 | NOVEL BICYCLIC UREA DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | disclosed |
| US-20040009968-A1 | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-01-15 | — | — | US | disclosed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | disclosed |
| CN-1440402-A | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-09-03 | — | — | CN | disclosed |
| WO-2003064397-A1 | INDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-1296978-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | disclosed |
| WO-2002002525-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | TAOK1 4776/4885CLK4 4425/4885CHEK1 3814/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | TAOK1 4776/4885CLK4 4425/4885CHEK1 3814/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | TAOK1 2568/4885CLK4 556/4885CHEK1 3536/4885 |
| US-20240287003-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | ACE2, ACE, TMPRSS2 | TAOK1 2286/4885CLK4 4849/4885CHEK1 2610/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | TAOK1 2272/4885CLK4 1781/4885CHEK1 4372/4885 |
| US-20040009968-A1 | Indazole compounds useful as protein kinase inhibitors | PRKD3, PDPK1, PDK1 | TAOK1 622/4885CLK4 1021/4885CHEK1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.